Study summary

Dazodalibep lowered disease activity and dryness in phase 3

OASIZ-301 trial · Phase 3 · Topline September 2026

What was tested

Dazodalibep, a fusion protein that blocks CD40 ligand signals between immune cells, against placebo in moderate to severe systemic Sjögren's disease.

What they found

• Both doses reduced systemic disease activity at week 48.
• The every-4-weeks dose also improved patient-reported dryness.
• A second phase 3 (OASIZ-303) in people with heavy symptoms but low systemic activity finishes late 2026.

What it means

A second likely option; approval would usually wait for the second trial.